Ospedale San Giovanni Bosco

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• IgA nephropathy5 trials
• Lupus (SLE)5 trials
• Dermatomyositis and polymyositis (myositis)2 trials
• Colorectal cancer1 trial
• Diffuse large B-cell lymphoma1 trial
• Immune thrombocytopenia (ITP)1 trial
• Rheumatoid arthritis1 trial

Phase

• Phase 25 trials
• Phase 34 trials
• Phase 11 trial
• Phase 2/31 trial
• Phase 41 trial

Status

• Recruiting5 trials
• Completed4 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Alexion Pharmaceuticals Inc.2 trials
• Hoffmann-La Roche2 trials
• Amgen1 trial
• Biogen1 trial
• Chugai Pharmaceutical1 trial
• and 5 more

Running trials

• Recruiting

  A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  NCT07598396· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Amgen· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

  NCT06371417· Phase 1· Chugai Pharmaceutical· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

  NCT04662723· Phase 4· Fondazione Schena· Source

• Active, not recruiting

  Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  NCT05126277· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced rectal cancer. A multi-arm, multi-stage, intergroup (STAR-04/SICO-CR01/GISCAD/AIRO-GI) randomised clinical trial. The NeoAspMet trial

  2024-519007-10-00· Phase 2/3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• IgA nephropathy2 recruiting
• Lupus (SLE)2 recruiting
• Colorectal cancer1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Rheumatoid arthritis1 recruiting

Closed trials

• Completed

  A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

  NCT05695950· Phase 2· Lakefront Biotherapeutics NV· Source

• Completed

  Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

  NCT05097989· Phase 2· Alexion Pharmaceuticals Inc.· Source

• Completed

  Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

  NCT04564339· Phase 2· Alexion Pharmaceuticals Inc.· Source

• Recruiting

  Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

  NCT04442412· Phase 3· Fondazione Italiana Linfomi - ETS· Source